These studies highlight the crucial involvement of MDM2 in the development, progression, invasiveness, and resistance to therapy of BC, through both p53-dependent and p53-independent mechanisms, outlining potential therapeutic opportunities for intervention. Here, TP53 is linked to breast cancer.